Every Question About Weight Loss Injections — Answered

Ozempic vs. Wegovy: Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved for chronic weight management (higher dose: 2.4 mg vs. 2 mg).

Mounjaro vs. Zepbound: Both contain tirzepatide by Eli Lilly. Mounjaro is approved for diabetes; Zepbound is approved for weight loss. Same drug, different brand names for different indications.

Saxenda (Liraglutide): A GLP-1 medication given daily (not weekly), FDA-approved for weight management. Older than the others and produces less dramatic weight loss (5–10% vs. 15–21% for Wegovy/Zepbound) but has a longer safety track record.

Key differentiator: Mounjaro and Zepbound activate two hormone pathways (GLP-1 + GIP), making them the most potent for weight loss. Ozempic, Wegovy, and Saxenda activate one (GLP-1 only).

As of 2025–2026, Zepbound (tirzepatide 15 mg) produces the greatest average weight loss in clinical trials — up to 21% of total body weight over 72 weeks.

Rankings by average clinical trial weight loss:

• Zepbound — up to 21% body weight loss (72 weeks)
• Wegovy — up to 15–17% body weight loss (68 weeks)
• Mounjaro — 12–25 lbs (52 weeks in diabetic patients)
• Ozempic — significant loss; approved for diabetes, off-label for weight
• Saxenda — approximately 5–10% body weight loss (56 weeks)

Real-world outcomes are typically 2–8% at one year due to adherence. Results are best combined with a reduced-calorie diet and regular exercise.

Mounjaro and Zepbound are the same drug (tirzepatide) made by Eli Lilly — just approved for different conditions:

The same relationship exists between Ozempic (diabetes) and Wegovy (weight loss) — both are semaglutide, different brand names.

Mounjaro (tirzepatide) is generally more effective than Ozempic (semaglutide) for weight loss and blood sugar control. Mounjaro targets two receptors (GLP-1 and GIP) vs. Ozempic’s one (GLP-1), leading to higher weight loss (up to 22.5% vs. ~15%).

However, “better” depends on your individual goals: Ozempic has a longer cardiovascular safety record and is more commonly covered by insurance for diabetes. Mounjaro and its weight-loss version Zepbound are the newer, more potent option. Your provider will recommend the best fit for your health profile.

All five medications work by mimicking natural gut hormones your body releases after eating:

• Slow stomach emptying → you feel full longer after meals
• Signal the brain to reduce hunger and appetite
• Regulate blood sugar by stimulating insulin when needed

Tirzepatide (Mounjaro and Zepbound only) also activates GIP receptors — a dual-action mechanism believed to explain why these produce greater weight loss than single-hormone GLP-1 drugs. These medications don’t “burn fat” directly — they fundamentally reset your appetite and metabolism.

Most patients notice reduced appetite within 1–4 weeks. Measurable weight loss typically begins by weeks 4–8. Long-term clinical outcomes at maximum doses:

• Zepbound (72 weeks): ~21% average body weight loss
• Wegovy (68 weeks): ~15% average body weight loss
• Mounjaro (52 weeks, diabetic patients): 12–25 lbs average
• Saxenda (56 weeks): ~5–10% average body weight loss

Some patients lose 15–20 lbs within the first 3 months on Zepbound combined with diet and exercise. Results vary by individual health, dosage, diet, and adherence.

Research shows that many patients regain a significant portion of lost weight after stopping GLP-1 medications if lifestyle habits haven’t changed. These medications treat obesity as a chronic disease — similar to how blood pressure medication must be taken long-term to maintain results.

However, newer studies indicate that nearly half of patients who stop GLP-1 injections maintain meaningful weight loss long-term when combined with sustained diet and exercise changes. Your provider will help you build a sustainable long-term plan.

All five are subcutaneous injections — injected just under the skin, not into a vein or muscle. Common injection sites:

• Abdomen (stomach area) — most common
• Upper thigh
• Upper arm

Frequency: Saxenda (liraglutide) is once daily; Ozempic, Wegovy, Mounjaro, and Zepbound are all once weekly. All come as easy-to-use auto-injector pens or prefilled syringes. Your provider or pharmacist will train you — most patients self-inject at home with no difficulty.

The four primary FDA-approved weight loss injection types are:

• Wegovy (semaglutide) — weekly GLP-1, FDA-approved for weight loss
• Zepbound (tirzepatide) — weekly GLP-1/GIP dual agonist, FDA-approved for weight loss
• Saxenda (liraglutide) — daily GLP-1, FDA-approved for weight loss
• Ozempic (semaglutide) — weekly GLP-1, FDA-approved for diabetes, widely used off-label for weight loss

All four act on the brain to reduce appetite and slow digestion, producing 5–21% body weight loss depending on the medication when combined with diet and exercise.

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist — it mimics one gut hormone to reduce appetite and regulate blood sugar.

Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist — it activates two hormone pathways, which is believed to contribute to its greater weight loss effects and potentially fewer reported GI side effects compared to semaglutide.

In head-to-head comparisons, tirzepatide generally produces greater weight loss (up to 22.5%) than semaglutide (~15%). Both are available at Weight Loss RX with a valid prescription.

Yes — through a licensed US pharmacy with a valid prescription. Weight Loss RX (weightlossinjection.us) is a licensed pharmacy dispensing all five FDA-approved weight loss injections with free shipping to all 50 states.

Important: The FDA warns against purchasing from unverified online sources. In April 2025, the FDA banned compounded (counterfeit) semaglutide and tirzepatide. Only purchase from a state-licensed pharmacy like Weight Loss RX to ensure you receive authentic, FDA-approved medications.

You need a prescription from a licensed provider. We can connect you with telehealth providers serving all 50 states — no in-person visit required.

Yes. All five medications — Ozempic, Wegovy, Mounjaro, Saxenda, and Zepbound — are prescription-only in the United States. You cannot legally purchase them without a valid prescription.

Weight Loss RX partners with telehealth providers who evaluate your eligibility online and send a prescription directly to our pharmacy — no in-person office visit required. We ship to all 50 states.

Typical eligibility: BMI ≥ 30, or BMI ≥ 27 with a weight-related condition (for Wegovy, Zepbound, Saxenda). Ozempic and Mounjaro require type 2 diabetes for on-label use.

FDA-approved eligibility for Wegovy, Zepbound, and Saxenda (weight loss):

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 (overweight) + at least one weight-related condition: high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea

Ozempic and Mounjaro: Require type 2 diabetes for on-label use; doctors may prescribe off-label for weight management.

For adolescents: Wegovy and Saxenda are approved for patients aged 12 and older. Your licensed provider will determine eligibility based on your complete health history.

Absolutely yes. You do not need diabetes to qualify. Three of the five medications are FDA-approved specifically for non-diabetic weight loss:

• Wegovy (semaglutide) — FDA-approved for weight loss in non-diabetic adults & teens 12+
• Zepbound (tirzepatide) — FDA-approved for weight loss in non-diabetic adults
• Saxenda (liraglutide) — FDA-approved for weight loss in non-diabetic adults & teens 12+

Ozempic and Mounjaro are technically approved for diabetes but may be prescribed off-label for weight management by your physician.

Getting started is simple — here’s how it works at Weight Loss RX:

1. Step 1: Visit weightlossinjection.us and fill out our quick eligibility form
2. Step 2: Connect with a licensed telehealth provider for a virtual consultation (available in all 50 states)
3. Step 3: If eligible, your provider writes a prescription sent directly to Weight Loss RX
4. Step 4: We fill your prescription and ship it discreetly to your door — anywhere in the USA
5. Step 5: Ongoing support from our licensed pharmacists and patient care team

We carry Ozempic, Wegovy, Mounjaro, Saxenda, and Zepbound — free shipping to all 50 states.

Yes — when purchasing from a licensed, state-regulated pharmacy. The FDA explicitly warns against buying from unverified sources, which may sell counterfeit or compounded versions containing wrong dosages or harmful substances.

Signs of a trustworthy online pharmacy:

• Licensed and verified by a state pharmacy board
• Requires a valid prescription before dispensing
• Only dispenses FDA-approved, brand-name medications
• Has licensed pharmacists available for consultation
• Provides clear contact information and a physical US address

Weight Loss RX meets all of these standards. We are fully licensed, veteran-owned, and dispense only authentic, FDA-approved medications.

Standard retail list prices per month (without insurance):

• Wegovy — ~$1,349/month list price
• Ozempic — ~$1,028/month list price
• Zepbound — ~$1,000+/month list price
• Mounjaro — ~$1,000+/month list price
• Saxenda — ~$1,300+/month list price

Savings programs reduce costs significantly:

• Wegovy: As low as $199/month for new patients (NovoCare savings program)
• Zepbound: As low as $349–$499/month (Eli Lilly direct vials program)
• Ozempic: As low as $349/month self-pay (NovoCare)

Contact Weight Loss RX — our team helps you access every available savings program for your medication.

Coverage varies significantly:

• Ozempic & Mounjaro (for diabetes): Covered by most commercial and Part D plans when prescribed for type 2 diabetes
• Wegovy, Zepbound, Saxenda (for weight loss): Covered by approximately 49% of large employer plans (500+ employees) as of 2025
• Medicare: Currently does NOT cover these for weight management — though Medicare negotiated pricing (~$274/month for Ozempic/Wegovy) takes effect in 2027
• Medicaid: Coverage varies by state

Even without insurance, manufacturer savings programs can dramatically reduce your cost. Weight Loss RX will help you navigate every available savings option.

Saxenda (liraglutide) remains a valuable option in several situations:

• Your insurance covers Saxenda but not Wegovy or Zepbound
• You or your doctor prefer daily dosing over a weekly injection
• You have experienced side effects with weekly semaglutide or tirzepatide
• You are a teenager aged 12–17 (both Saxenda and Wegovy are approved for adolescents 12+)

While Saxenda typically produces less weight loss (5–10%) than Wegovy or Zepbound (15–21%), it has been on the market since 2014 with a well-established safety profile. It remains an FDA-approved, legitimate choice.

Common side effects (especially when starting or increasing dose):

• Nausea (most common — usually improves over time)
• Vomiting
• Diarrhea or constipation
• Stomach pain or bloating
• Decreased appetite
• Fatigue

Rare but serious risks: pancreatitis, gallbladder disease, kidney injury, and a theoretical thyroid C-cell tumor risk (seen in animal studies; not confirmed in humans). These medications carry a black box warning for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Always disclose your complete medical history to your provider before starting any of these medications.

For most healthy adults under medical supervision, these medications are considered safe and well-studied through rigorous FDA review.

Potential long-term risks being monitored:

• Pancreatitis (inflammation of the pancreas)
• Gallbladder disease (gallstones)
• Kidney injury (particularly in patients prone to dehydration)
• Thyroid C-cell tumors (animal studies only; not confirmed in humans)
• “Ozempic face” — facial volume loss due to rapid weight loss
• Hair loss (reported in some patients)

The FDA continuously monitors post-market safety data. Benefits typically outweigh risks for eligible patients under proper medical supervision.

Compounded semaglutide and tirzepatide are versions of these drugs made by non-manufacturer pharmacies — they are NOT FDA-approved. The FDA banned their sale in April 2025 due to serious safety concerns.

Why compounded versions are dangerous:

• May contain incorrect amounts of active ingredients
• May contain wrong ingredients or harmful additives
• Not subject to FDA quality controls or manufacturing standards
• The FDA has received reports of serious adverse events from patients using compounded versions

What Weight Loss RX provides: Only authentic, brand-name, FDA-approved medications — Ozempic, Wegovy, Mounjaro, Saxenda, and Zepbound — sourced directly from licensed US distributors. You will never receive a compounded product from us.

Saxenda® (liraglutide 3 mg) is an FDA-approved once-daily injectable prescription medicine for:

• Adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related medical problem
• Children aged 12–17 with a body weight above 132 lbs (60 kg) and obesity

It should be used with a reduced-calorie diet and increased physical activity. It is not recommended for people also taking other GLP-1 receptor agonists.

Saxenda is injected once daily — at any time, independent of meals, at the same time each day. The dose escalation schedule:

• Week 1: 0.6 mg/day
• Week 2: 1.2 mg/day
• Week 3: 1.8 mg/day
• Week 4: 2.4 mg/day
• Week 5+: 3.0 mg/day (maintenance dose)

This gradual increase is designed to minimize gastrointestinal side effects. Once the 3 mg dose is reached, each pen lasts 6 days.

Unused pens: Store in a refrigerator between 36°F–46°F (2°C–8°C).

After first use: Store in a refrigerator or at room temperature between 59°F–86°F (15°C–30°C). Use within 30 days. Do not freeze — frozen Saxenda must not be used.

Pen life: Once the 3 mg dose is started, each pen lasts approximately 6 days. Use Novo Nordisk disposable needles only. Dispose of used needles immediately in a sharps container — never in household trash.

Nausea is the most common side effect when starting Saxenda® but decreases over time as your body adjusts. Tips to manage nausea:

• Eat bland, low-fat foods (crackers, toast, rice)
• Choose foods with high water content (soups, gelatin)
• Don’t lie down immediately after eating
• Get some fresh air after meals
• Take your injection at bedtime so peak nausea occurs while sleeping

The gradual dose escalation schedule is specifically designed to reduce gastrointestinal symptoms. Always inform your provider about side effects that are bothersome or do not resolve.

Ozempic® (semaglutide injection 0.5 mg, 1 mg, or 2 mg) is FDA-approved for:

• Adults with type 2 diabetes — to improve blood sugar alongside diet and exercise
• Reducing the risk of major cardiovascular events (stroke, heart attack) in adults with type 2 diabetes and heart disease
• Reducing the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease

Ozempic is NOT FDA-approved for weight loss — its sister drug Wegovy (same ingredient, higher 2.4 mg dose) is the weight loss version. However, doctors frequently prescribe Ozempic off-label for weight management. There is also an Ozempic tablet version (semaglutide tablets 1.5 mg, 4 mg, 9 mg) coming soon.

Results vary significantly by individual. In the first 3 months, most patients experience:

• Appetite suppression beginning in the first few weeks
• 5–10% body weight loss by the 3-month mark at therapeutic doses
• Some patients lose 10–15+ lbs in 12 weeks when combined with a reduced-calorie diet and exercise

Key factors affecting results: dosage, diet quality, exercise habits, individual metabolism, and medical history. Long-term clinical studies show 10–15% total body weight loss over 68 weeks at the Wegovy dosing level (2.4 mg semaglutide).

Ozempic became a cultural phenomenon after high-profile use by celebrities and social media influencers drew widespread attention to its dramatic weight loss results. Social media amplified awareness well beyond its approved use for type 2 diabetes, creating massive demand across the USA.

This resulted in significant supply shortages in 2022–2024 and the FDA approving Wegovy (higher-dose semaglutide) specifically for weight management. If you see weight loss content about Ozempic or semaglutide online, always verify information with a licensed healthcare provider and pharmacy — not all social media claims are accurate or medically appropriate.

Yes — Weight Loss RX ships to every state in the USA. Whether you are in a major city or a rural area, we deliver Ozempic, Wegovy, Mounjaro, Saxenda, and Zepbound directly to your door with free shipping on every order.

We serve patients in all 50 states: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, and Washington D.C.

All shipments are handled discreetly with proper cold-chain packaging to maintain medication integrity.

Yes. Weight Loss RX (weightlossinjection.us) is a fully licensed US pharmacy operating under state and federal pharmacy law. We are:

• Registered with state boards of pharmacy
• Compliant with DEA and FDA regulations
• Veteran-owned and operated
• Only dispensing FDA-approved, brand-name medications
• Requiring a valid prescription for every order
• Based at 749 Golf View Dr #A, Medford, OR 97504

We are NOT a gray-market reseller, foreign pharmacy, or compounding operation. We are a legitimate, regulated, licensed US pharmacy — 500,000+ patients served.

Tirzepatide (Zepbound®) is currently the most effective FDA-approved weight loss medication available, with clinical trials showing average weight loss of 15–21%+ of total body weight. It outperforms earlier options by targeting both GIP and GLP-1 receptors.

Semaglutide (Wegovy®) is the highly effective runner-up at roughly 15% body weight loss. Both are available at Weight Loss RX with a valid prescription, with free shipping to all 50 states.

Buy Zepbound →  |  Buy Wegovy →